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Background: Asthma is estimated to affect as many as 300 million people worldwide and its incidence and
prevalence are rapidly increasing throughout the world, especially in children and within developing countries.
Recently, there has been a growing interest in the use of potentially beneficial bacteria for allergic diseases. This
study is aimed at exploring the therapeutic effects of long-term treatment with two different beneficial bacterial
strains (Bifidobacterium breve M-16 V and Lactobacillus rhamnosus NutRes1) and a glucocorticoid (budesonide), as a
reference treatment, on inflammatory response in a murine model for chronic allergic asthma.
Methods: To mimic the chronic disease in asthmatic patients, we used the murine ovalbumin-induced asthma
model combined with prolonged allergen exposure. Airway function; pulmonary airway inflammation; airway
remodelling, mRNA expression of pattern recognition receptors, Th-specific cytokines and transcription factors in
lung tissue; mast cell degranulation; in vitro T cell activation; and expression of Foxp3 in blood Th cells were
examined.
Results: Lactobacillus rhamnosus reduced lung resistance to a similar extent as budesonide treatment in chronically
asthmatic mice. Pulmonary airway inflammation, mast cell degranulation, T cell activation and airway remodelling
were suppressed by all treatments. Beneficial bacteria and budesonide differentially modulated the expression of
toll-like receptors (TLRs), nod-like receptors (NLRs), cytokines and T cell transcription factors. Bifidobacterium breve
induced regulatory T cell responses in the airways by increasing Il10 and Foxp3 transcription in lung tissue as well
as systemic by augmenting the mean fluorescence intensity of Foxp3 in blood CD4+ T cells.
Conclusion: These findings show that Bifidobacterium breve M-16 V and Lactobacillus rhamnosus NutRes1 have
strong anti-inflammatory properties that are comparable to budesonide and therefore may be beneficial in the
treatment of chronic asthma.
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Allergic asthma is a T helper type-2 (Th2) cell-mediated
chronic inflammatory disorder of the airways with ra-
pidly increasing incidence and prevalence throughout
the world, especially in children and within developing
countries [1]. It is characterised by airway inflammation
and hyper-responsiveness (AHR) [2]. Structural changes
in the airway walls of asthmatic patients, referred to as
“airway remodelling”, are caused by persistent inflam-
mation and subsequent inadequate repair of damaged
airway epithelium [3-5].
Various cells are involved in cellular airway inflam-
mation and subsequent airway remodelling, such as
eosinophils, neutrophils, T lymphocytes and mast cells
[4]. Infiltration of mast cells into the airway smooth
muscle cell layer of allergic asthmatics is a key feature of
asthma and is thought to be associated with AHR [6,7].
Upon mast cell degranulation various inflammatory me-
diators, such as vasoactive amines, cytokines and pro-
teases are released [8,9]. Mouse mast cell protease 1
(mMCP-1) was reported to enhance airway narrowing in
mice through effects on the epithelium [10,11].
Glucocorticoids (GCs) are by far the most effective
treatments for asthma [12]. Besides the undesirable side
effects of long-term GC therapy, a significant number of
asthmatics is steroid resistant and fails to respond to this
therapy [13,14]. These limitations of GCs therapy high-
light the need for novel therapeutics with long-term
benefits, greater disease control and increased efficacy.
Changes in the microbiota were reported to contribute
to the development of allergies and asthma [15,16]. The
potential role of beneficial bacteria, such as probiotics,
as modulators of the intestinal microbiota and mucosal
immune responses has been extensively investigated and
discussed in the last few years [17-19]. Probiotics are
“live microorganisms which, when consumed in ad-
equate amounts, confer a health benefit on the host”
[20,21]. Bifidobacteria and Lactobacilli, which are a part
of the gut microbiota, were effective in suppressing both
allergic and autoimmune responses, reducing allergic
symptoms and inhibiting allergic airway response in
murine models of acute airway inflammation [22-26].
Because they contain toll-like receptor (TLR) ligands,
it is believed that beneficial bacteria can modulate TLR-
driven responses and also skew the immune balance to-
wards a Th1-associated response [27]. The TLRs and
nod-like receptors (NLRs) are key pattern recognition
receptor (PRR) families in the innate immune response.
In the human airways, the RRRs are expressed in or on
dendritic cells (DCs), epithelial cells, eosinophils, mac-
rophages and mast cells [28,29]. Following TLR and
NLR activation in the lung, various chemokines and cy-
tokines are produced by eosinophils and mast cells that
attract activated B-lymphocytes and Th lymphocytes tothe lung to orchestrate the inflammation in the air-
ways [30].
The function and expression of PRRs were linked to
susceptibility towards allergic asthma [31,32]. Functional
genetic variations in TLR1, TLR10 and TLR6 genes affec-
ting gene and protein expression were associated with in-
creased mRNA expression of these TLRs and protected
against atopic asthma in humans [32]. Genetic variations
in TLR2, NOD1 and NOD2 genes that led to either de-
creased mRNA expression and affected microbial recogni-
tion, respectively, were positively associated with disease
susceptibility and pathogenesis [25,33-36]. Cord blood
CD34 (+) cells from high-atopic-risk infants have been re-
ported to have low TLR2, TLR4, and TLR9 expression and
the latter was demonstrated to exert protective immuno-
modulatory effects on asthma [37-39]. Tlr3 contributes to
asthma exacerbations in mice [40] and a study in a murine
macrophage cell line suggested a pro-inflammatory role of
Tlr4 and 5 in the disease [41].
In asthma, over 50 cytokines have now been identified
to affect disease outcome. Strong pro-inflammatory
and Th2-associated cytokines; including interleukin-1β
(IL-1β), IL-4, IL-5, IL-6, IL-9, IL-13, IL-17, IL-25 and
tumor necrosis factor α (TNF-α) were reported to
enhance asthma [30]. On the other hand, Th1-associated
cytokines; IL-12, IL-18 and interferon-γ (IFNγ) were re-
ported to reduce the symptoms of the disease [30]. Ad-
ditionally, subjects with asthma were reported to have
reduced levels of the anti-inflammatory cytokine IL-10 in
the sputum [42]. Moreover, Th1/Th2 imbalances as well as
disturbed T helper type-17(Th17)/Treg balances were
reported in asthmatic patients [43]. Imbalances in Th re-
sponses can also be detected using Th-specific transcrip-
tion factors: T-bet for Th1 cells, GATA-3 for Th2 cells,
retinoic acid orphan receptor-γt (RORγt) for Th17 cells
and forkhead box P3 (Foxp3) for Tregs [44]. Alterations in
the expression and/or function of Th-specific transcription
factors were associated with asthma pathogenesis [45,46].
This study aimed to explore the therapeutic effects of
long-term administration of Bifidobacterium breve M-16 V
and Lactobacillus rhamnosus NutRes1 on chronic airway
inflammation and remodelling in mice. A glucocorticoid
was used as a reference treatment. Findings from this
study will contribute to a better understanding of the im-
munomodulatory and therapeutic effects of beneficial bac-
teria in chronic allergic asthma.
Methods
Animals
Male BALB/c mice (6–8 weeks; Charles River Laboratories,
France) were acclimated to their new environment for at
least 1 week before the start of the experiment. Mice were
housed under standard conditions and had free access to
food and water. All in vivo experiments were approved by
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Dutch Committee of Animal Experimentation.
Chronic asthma model
OVA sensitisation
Sensitisations were performed on days 0 and 12. Mice
were sensitised to OVA (chicken egg albumin, grade V,
Sigma, St. Louis, MO, USA) by intraperitoneal injections
of 0.1 mL alum-precipitated antigen, comprising 10 μg
OVA absorbed into 2.25 mg alum (AlumImject; Pierce,
Rockford, IL, USA). Control animals received 0.1 mL
saline only (NaCl 0.9%; B. Braun Medical B.V., Oss, The
Netherlands) (Figure 1).
OVA challenge
A chronic model of asthma was established according to a
modification of a model of prolonged allergen-induced
airway inflammation described in [2]. Mice were exposed
daily to 5% OVA aerosol in saline or saline only using a
Pari LC Star nebuliser (PARI GmbH, Starnberg, Germany)
in an aerosol cabin for 20 min between days 17 and 23.
Control animals were exposed to nebulised saline aerosol
only. From day 24 until day 55, the frequency of challenge
was reduced to three times a week and mice were exposed
to aerosolised OVA (5%) or saline only for 20 min
(Figure 1).
Beneficial bacteria treatment
Bifidobacterium breve M-16 V (B. breve, Morinaga Milk
Industry, Tokyo, Japan) and Lactobacillus rhamnosus
NutRes1 (L. rhamnosus, Danone Research, Wageningen,
the Netherlands) were grown in MRS (Oxoid, Basingstoke,
UK), supplemented with 0.5 g/L L-cysteine for Bifidobac-
teria, at pH 6.5 and under anaerobic conditions. BacteriaFigure 1 Time schedule of the chronic asthma mouse model. Male BA
0 and 12 and mice were challenged from day 17 until day 23 daily with ae
3 times a week with either PBS or budesonide by oropharyngeal aspiration
after treatment, from day 24 until day 55, mice were challenged 3 times/w
pulmonary function measurement.were harvested in the early stationary phase, washed with
phosphate buffered saline (PBS, Lonza Leusden, The
Netherlands) and stored with glycerol 20% (w/v), in ali-
quots at −80°C. Cell counts were determined by plating
serial dilutions and fluorescent microscopy by staining
with DAPI. The bacteria were resuspended in PBS prior to
use.
After development of airway inflammation, mice re-
ceived 109 colony forming units (CFUs) of B. breve or
1.1 × 109 CFUs of L. rhamnosus per animal per day. Bac-
terial strains were suspended in 0.2 mL of PBS and given
by oral gavage, 1 h prior to challenge, three times a week
from day 22 until day 55 (Figure 1).
Budesonide treatment
As a reference treatment, mice received 0.5 μg/g of
mouse/day of budesonide (Sigma) in PBS. Budesonide
was administered to mice by oropharyngeal aspiration
after induction of light isoflurane anesthesia as described
previously in [47], 1 h prior challenge, three times a
week from day 22 until day 55. Control animals received
50 uL of PBS by the same administration route. Mice
were rendered asthmatic following the schema presented
in Figure 1.
Airway response to methacholine
On day 56, 24 h after the last OVA aerosol challenge, the
airway response to increasing doses of methacholine was
analysed after insertion of a cannula in the trachea. Lung
resistance in anesthetized, mechanically ventilated mice
was measured directly using whole-body plethysmography
(Emka technologies, Paris, France). Mice were exposed to
saline (0 mg/mL methacholine) and increasing doses (0.38
to 25 mg/mL) of aerosolised methacholine (Sigma).LB/c mice were sensitised intraperitoneally to OVA-ImjectAlum on days
rosolised OVA or saline. From day 22 until day 55, mice were treated
or beneficial bacteria (B. breve or L. rhamnosus) by oral gavage. 1 h
eek with aerosolised OVA or saline. Mice were sacrificed on day 56 after
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After sacrifice, on day 56, lungs were first lavaged
through a tracheal cannula with 1 mL saline containing
protease inhibitor cocktail (Complete Mini, Roche Diag-
nostics, Mannheim, Germany), pre-warmed at 37°C.
This was followed by 3 additional lavages with 1 mL sa-
line only. Cytospin cell preparations were made by
cytospinning the cells onto glass for 5 min (400 g, 4°C)
and cytospins were stained by DiffQuick (Merz & Dade
AG, Düdingen, Switzerland). Numbers of eosinophils,
macrophages, neutrophils and lymphocytes were scored
by light microscopy.RNA isolation and quantitative real-time PCR
After mice were sacrificed on day 56, the lungs were dis-
sected and mRNA was isolated from whole lung tissue.
Messenger RNA isolation (n = 6 mice per group) was car-
ried out according to the Qiagen RNeasy Mini Kit protocol
(Qiagen Benelux B.V., Venlo, The Netherlands). Reverse
transcriptase PCR was performed using an iScript™cDNA
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA).
The reactions were performed in a PTC-100TM Pro-
grammable Thermal Controller (M. J. Research Inc.,
Waltham, Massachusetts, USA) according to manufac-
turer’s protocol.
cDNA was amplified using iQ SYBR Green supermix in
a 96-well PCR plate and run in a CFX96 Real-Time PCR
Detection System (Bio-Rad). Primers for TLRs, NLRs,
ribosomal protein S13 (RPS13, reference gene) and T cell
transcription factors were purchased by Isogen (Isogen
Life Science, De Meern, The Netherlands). The sequences
are listed in Additional file 1: Table S1. For mouse T cell
cytokines, RT2 qPCR Primer Assays (SABiosciences,
Venlo, The Netherlands) were used. The protocol used for
amplification was 94°C for 3 min, 94°C for 10 sec, specific
melt temperature for 45 sec, followed by 39 cycles of 94°C
for 10 sec and 95°C for 10 sec.
Normalised gene expression (ΔΔCT) was calculated
using the built-in gene expression analysis module in CFX
Manager™ software (CFX Manager™ software version 1.6).Foxp3 staining and flow cytometry
On days 0 and 56, blood samples were collected from
mice by cardiac puncture in tubes containing lithium he-
parin to prevent coagulation. The blood was then washed
in PBS and, after centrifugation; the pellet was subjected
to red cell lysis using a buffer containing NH4Cl (MERCK,
Darmstadt Germany), KHCO3 (Sigma), ethylenediamine-
tetraacetic acid (EDTA, MERCK) in demineralised water
for 5 min on ice. After several washes with PBA (PBS con-
taining 1% bovine serum albumin (BSA, Roche Diagnos-
tics, Almere, The Netherlands) cells were resuspended in
PBA and kept on ice until Foxp3 staining.The expression of Foxp3 was measured using the Foxp3
Staining Buffer Set (eBioscience, San Diego, CA, USA)
using the following protocol: cells were incubated in Fixa-
tion/Permeabilization buffer for 30 min on ice. Cells were
then washed once with PBA followed by two washes with
permeabilization buffer. After a 15 min preincubation in
total mouse serum blocking reagent on ice, cells were
washed once with permeabilization buffer and then
stained with anti-CD4 (FITC, eBioscience), anti-CD25
(PE, eBioscience) and anti-Foxp3 (APC, eBioscience)
for 30 min on ice. Cells were washed twice with per-
meabilization buffer and resuspended in PBA for flow cy-
tometry analysis.
Tregs were defined as CD4 + Foxp3 + CD25hi T cells.
The stained cells were analysed on a FACSCanto II flow
cytometer (BD Biosciences, USA). Data analysis was per-
formed using BD FACSDiva™ software (BD Biosciences).
The gating strategy is illustrated in Additional file 2:
Figure S1.
Measurement of mouse mast cell protease 1 levels in
serum
To assess mast cell activation, after mice were sacrificed
on day 56, blood samples were collected from mice by car-
diac puncture. The blood was coagulated for 1 h at room
temperature and subsequently centrifuged for 5 min at
17,500 g. Serum samples were stored at −80°C until fur-
ther analysis. Mouse mast cell protease 1 (mMCP-1)
protein expression levels in serum were determined by
enzyme-linked immunosorbent assay (ELISA) using the
Mouse MCPT-1 (mMCP-1) ELISA Ready-SET-Go!® kit
(eBioscience) according to manufacturer’s protocol.
Measurement of cytokine production by T cells in
thoracic lymph nodes after restimulation with anti-CD3
antibody in vitro
In order to examine specific T cell responses, after mice
were sacrificed on day 56, lung-draining lymph nodes
were collected from the thorax and transferred to cold
sterile PBS. Single cell suspensions of the thoracic lymph
nodes (TLNs) were made using a 70 μm nylon cell strainer
(BD Biosciences) and rinsed with 15 mL of PBS. The cells
were washed and resuspended in RPMI 1640 culture
medium without L-glutamine and phenol red (Lonza)
supplemented with 10% heat-inactivated fetal calf serum
(FCS, Hyclone Laboratories, USA) and 0.1% penicillin-
streptomycin solution (pen-strep, Sigma). The total num-
ber of cells was determined using a Beckman Z1 coulter®
Particle Counter (Beckman, USA). TLN cells (4 × 106
cells/mL) were cultured in a Greiner bio-one CellSTAR
96-well U-bottom plate (Greiner Bio-One B.V., Alphen
a/d Rijn, The Netherlands) in medium with or without
O/N pre-coating of the wells with 50 μg/mL of anti-CD3
antibody (Bioceros BV, Utrecht, The Netherlands). The
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in 5% CO2 and stored at −20°C until further analysis.
The levels of cytokines in the supernatant were mea-
sured by flow cytometry using a BD™ Cytometric Bead
Array (CBA) Mouse Th1/Th2/Th17 Cytokine kit (BD
Biosciences) according to manufacturer’s protocol on a
FACSCanto II flow cytometer (BD Biosciences). Data
analysis was performed using BD FCAP Array™ v3.0.1
Software (BD Bisosciences).
Histology and immunohistochemistry
After mice were sacrificed on day 56, lungs were fixed
with 10% formalin infusion through a tracheal cannula at
a constant pressure of 25 cm H2O. The lungs were
immersed in fixative for at least 24 h, after which the left
lung was embedded in paraffin. After paraffin embedding,
5 μm sections were cut and de paraffin sections were first
deparaffinised. Endogenous peroxidase activity was
blocked with 0.3% H2O2 (Merck) in methanol for 30 min
at room temperature and rehydrated in a graded ethanol
series to PBS and paraffin section were stained with
hematoxylin/eosin (H&E) for inflammation, periodic acid-
schiff (PAS) for goblet cells, Masson’s trichrome for
connective tissue, rabbit polyclonal anti-α-smooth muscle
actin antibody (Abcam, Cambridge, UK) for smooth
muscle cells and rabbit polyclonal anti-Ki76 antibody
(Abcam) for proliferating cells according to standard
methods. Photomicrographs were taken with an Olympus
BX50 microscope equipped with a Leica DFC 320 digital
Camera.
Slides were reviewed in blinded fashion by two ob-
servers independently and slides were scored on the
basis of the percentage of positive stained cells in the
following way: −, no positive staining; +/−, less than 25%
of cells stained positive; +, 25 to 50% cells stained posi-
tive; ++, 50 to 75% cells stained positive.
Statistical analysis
Data analysis was performed using a 1-way analysis of
variance (one-way ANOVA) with the Bonferroni’s post-
hoc test. Linear regression analysis was used to calculate
correlations. All statistical analyses were performed using
GraphPad Prism software program (GraphPad Prism soft-
ware version 5.03).
Results
L. rhamnosus and budesonide reduce the increased lung
resistance in chronically asthmatic mice
To investigate the lung function in the chronic asthmatic
mice after treatments, lung resistance was measured
(Table 1). OVA-sensitised and challenged control mice
(OVA/OVA-PBS) showed a significant increase in the
basal lung resistance and lung resistance at all concentra-
tions of methacholine as compared to the sensitised onlycontrol group (OVA/Sal-PBS). Treatment of sensitised
and challenged mice with L. rhamnosus (OVA/OVA-
L. rhamnosus) resulted in a significant decrease in the
basal lung resistance and lung resistance at 0, 0.75 and
1.56 mg/mL methacholine as compared to the OVA/
OVA-PBS group. Budesonide treatment significantly de-
creased the basal lung resistance and lung resistance at 0,
0.38, 0.75 and 1.56 mg/mL methacholine in allergic mice
(OVA/OVA-BUD) as compared to OVA/OVA-PBS mice.
The basal lung resistance and lung resistance at all con-
centrations of methacholine remained unchanged in
B. breve-treated, sensitised and challenged mice (OVA-
OVA-B. breve) as compared to the OVA/OVA-PBS group.
B. breve and L. rhamnosus are as effective as budesonide
in reducing pulmonary inflammation in chronically
asthmatic mice
To gauge the extent of inflammation in the asthmatic
mice after treatments, bronchoalveolar lavage (BAL) fluid
was examined for leukocyte accumulation (Figure 2).
OVA/OVA-PBS mice showed a significant increase in
the total inflammatory cell number (155.25 × 104 ± 12.58;
n = 6; p < 0.0001) in the BAL fluid, which was due to a
relative increase in the number of macrophages, eosino-
phils and neutrophils as compared to OVA/Sal-PBS mice
(29.25 × 104 ± 3.12; n = 6). All treatments significantly re-
duced the total number of inflammatory cells in the BAL
fluid of OVA/OVA mice. Budesonide treatment signifi-
cantly decreased the total inflammatory cell number
(83.70 × 104 ± 13.66; n = 6; p < 0.0001) and relative num-
ber of eosinophils and neutrophils in OVA/OVA-BUD
mice. B. breve treatment, however, further decreased the
total inflammatory cell number (73.50 × 104 ± 6.42, n = 6;
p < 0.0001) and significantly decreased the relative number
of eosinophils and neutrophils. L. rhamnosus treatment
significantly decreased the total inflammatory cell number
(79.75 × 104 ± 17.49; n = 6; p < 0.0001) and relative num-
ber of neutrophils.
B. breve and L. rhamnosus modulate TLR and NLR mRNA
expression in lung tissue of chronically asthmatic mice
As PRRs in the lung can modulate ongoing chronic
inflammation during asthma, the mRNA expression of
Tlr1-9 and Nod1-2 were measured (Figure 3). The mRNA
expression of Tlr3 and Nod1 was significantly decreased
and Tlr9 was also decreased (p > 0.05) in OVA/OVA-PBS
mice as compared to the OVA/Sal-PBS group (Figure 3A).
After B. breve treatment, the OVA/OVA-B. breve mice
showed a significant increase in Tlr9 expression compared
to the OVA/OVA-PBS group. In non-asthmatic controls,
Tlr1 and Tlr2 expression was significantly increased in
the OVA-Sal-B. breve group as compared to OVA/Sal-PBS
mice, yet, the expression of the other PRRs in non-asth-
matic controls remained unchanged. B.breve treatment in
Table 1 L. rhamnosus and budesonide treatment reduce the basal lung resistance in chronic asthmatic mice
Group Methacholine (mg/mL)
Basal 0 (saline) 0.38 0.75 1.56 3.13 6.25 12.5 25
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
OVA/Sal-PBS 0.73 0.09 0.76 0.09 0.80 0.06 0.88 0.06 0.97 0.08 1.04 0.09 1.16 0.06 1.23 0.07 1.41 0.12
OVA/OVA-PBS 1.81# 0.31 1.79# 0.22 1.76# 0.19 1.85# 0.20 1.86# 0.21 1.82# 0.19 1.73# 0.15 1.96# 0.18 2.01# 0.21
OVA/Sal-B. breve 0.61 0.09 0.76 0.15 0.93 0.21 0.96 0.17 0.97 0.13 1.00 0.07 1.12 0.09 1.17 0.09 1.16 0.06
OVA/OVA-B. breve 1.74 0.58 1.66¤ 0.59 1.54 0.43 1.55 0.33 1.66 0.28 1.86 0.30 1.97 0.27 2.18 0.29 2.36 0.30
OVA/Sal-L. rhamnosus 0.64 0.09 0.73# 0.16 0.74 0.09 0.81 0.11 0.83 0.08 0.93 0.08 1.02 0.10 1.05 0.08 1.20 0.12
OVA/OVA-L.
rhamnosus
1.05¤ 0.18 1.15¤ 0.14 1.13 0.13 1.18¤ 0.13 1.30¤ 0.12 1.48 0.13 1.55 0.14 1.69 0.16 1.80 0.16
OVA/Sal-BUD 0.55 0.02 0.56# 0.02 0.63 0.04 0.71 0.07 0.79 0.09 0.85 0.10 0.96 0.09 1.08 0.12 1.17 0.11
OVA/OVA-BUD 0.85¤ 0.12 0.88¤ 0.09 1.01¤ 0.09 1.10¤ 0.09 1.23¤ 0.13 1.38 0.13 1.57 0.15 1.73 0.10 1.80 0.16
Airway response to saline and increasing doses of methacholine measured 24 h after the last OVA or saline challenge as expressed by lung resistance (LR). Basal
airway response is also shown. Mice in all groups were sensitised to OVA. OVA/Sal mice were challenged with saline; OVA/OVA mice were challenged with OVA.
Mice were treated with PBS (OVA/Sal-PBS; OVA/OVA-PBS), B. breve (OVA/Sal-B. breve; OVA/OVA-B. breve), L. rhamnosus (OVA/Sal-L. rhamnosus; OVA/OVA-L.
rhamnosus) or budesonide (OVA/Sal-budesonide; OVA/OVA-budesonide). Results are shown as mean ± SEM, n = 6 mice/group. Statistical significance of differences
was tested using post hoc Bonferroni’s multiple comparison test after one-way ANOVA. #Statistically significant difference (p < 0.05) compared to OVA/Sal-PBS
mice. ¤Statistically significant difference (p < 0.05) compared to OVA/OVA-PBS mice. BUD = budesonide.
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and decreased Tlr2, Tlr3, Tlr5 and Nod1 expression in
the OVA/OVA-B. breve group as compared to the OVA-
Sal-B. breve group (Figure 3B). Mice in the OVA/OVA-
budesonide group showed significant increases in the
expression of Tlr3 and Nod1 and Tlr9 expression was
higher (p > 0.05) as compared to the OVA/OVA-PBS
group. The expression of Tlr3 and Tlr5 was significantly
decreased in OVA/Sal-budesonide mice as compared to
the OVA/Sal-PBS group (Figure 3C). The OVA/OVA-
L. rhamnosus group showed a significant decrease in Tlr4,
an increase in Tlr3 and higher Tlr9 expression compared
to OVA/OVA-PBS mice. The mRNA expression of Tlr1,
Tlr2, Tlr4, Tlr6, Nod1 and Nod2 was significantly de-
creased in OVA/OVA- L. rhamnosus mice as compared to
the OVA/Sal-L. rhamnosus group (Figure 3D).
Beneficial bacteria and budesonide treatment modulate
cytokine mRNA expression in lung tissue of chronically
asthmatic mice
To determine the extent of inflammation and the Th re-
sponse in the lung, the mRNA expression of various cyto-
kines was measured (Figure 4). The mRNA expression of
Il1β and Il6 was significantly increased and Il13 and Il17
expression was also increased (p > 0.05) in OVA/OVA-
PBS mice as compared to the OVA/Sal-PBS group
(Figure 4A). The OVA/OVA-B. breve group showed a sig-
nificant increase in Il4 and Il10 expression as compared to
the OVA/OVA-PBS group. Expression of Il1β and Il6 was
significantly increased in OVA/Sal-B. breve mice as com-
pared to the OVA/Sal-PBS group. The mRNA expression
of these two cytokines was significantly decreased in
OVA/OVA-B. breve mice as compared to the OVA/Sal-
B. breve group (Figure 4B). The OVA/OVA-budesonidegroup showed a significant decrease in the expression of
Tnfα as compared to OVA/OVA-PBS mice. Expression of
Il13 was significantly increased and Tgfβ expression was
significantly decreased in OVA/Sal-budesonide mice as
compared to the OVA/Sal-PBS group. The mRNA expres-
sion of Il23 and Tgfβ was significantly increased in OVA/
OVA-budesonide mice as compared to the OVA/Sal-
budesonide group (Figure 4C). L. rhamnosus treatment
significantly decreased the expression of Il6 in OVA/
OVA-L. rhamnosus mice as compared to the OVA/OVA-
PBS group. The expression of Il1β, Il6 and Ifnγ was sig-
nificantly increased and Tgfβ expression was significantly
decreased in OVA/Sal-L. rhamnosus mice compared to
the OVA/Sal-PBS group. The mRNA expression of Il1β
and Il6 was significantly decreased in OVA/OVA-L. rham-
nosus mice as compared to the OVA/Sal-L. rhamnosus
group (Figure 4D).
B. breve treatment results in a strong up-regulation of
mRNA for Tbet and Foxp3 and relevant Th cytokines
mRNA expression in the lungs of chronically asthmatic
mice
To further explore the effects of the different treatments on
Th responses in the lung, the mRNA expression of Th-
specific transcription factors was measured (Figure 5). The
expression of Th1-(Tbet) and Treg-(Foxp3) transcription
factors was significantly decreased in the OVA/OVA-PBS
group as compared to the OVA/Sal-PBS group. No correla-
tions were found between the expression of these transcrip-
tion factors and relevant Th cytokines. The expression of
Th2-(Gata3), and Th17-(Rorγt) transcription factors
remained unchanged (Figure 5A). However,Tbet and Foxp3
expression was significantly increased in OVA/OVA-B.
breve mice as compared to the OVA/OVA-PBS group.
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M
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E
N
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Figure 2 Beneficial bacteria and budesonide reduce the differential BAL fluid cell counts in chronic asthmatic mice. Pulmonary
inflammation is represented by the influx of macrophages (M), lymphocytes (L), eosinophils (E) and neutrophils (N) in the BAL fluid. Differential
cell counts are shown as percentages of the total cell count for each group. The charts show the mean, n = 6 mice/group. Statistical significance
of differences was tested using post hoc Bonferroni’s multiple comparison test after one-way ANOVA. #Statistically significant difference (p < 0.05)
compared to OVA/Sal-PBS mice. ¤Statistically significant difference (p < 0.05) compared to OVA/OVA-PBS mice. ‡Statistically significant difference
(p < 0.05) compared to the OVA/Sal group in each treatment group. BUD = budesonide.
Sagar et al. Respiratory Research 2014, 15:46 Page 7 of 17
http://respiratory-research.com/content/15/1/46Interestingly, expression of Tbet was tightly correlated with
Ifnγ (R2 = 0.903; p = 0.013) and Il12 (R2 = 0.994; p = 0.003)
and expression of Foxp3 was tightly correlated with Il10
(R2 = 0.860; p = 0.024) expression in whole lung tissue of
OVA/OVA-B. breve mice. Compared to the OVA/Sal-PBS
group, Foxp3 expression was almost two-fold increased
(P > 0.05) in the OVA/Sal-B. breve group. Expression of
Tbet was significantly increased and expression of Gata3was significantly decreased in OVA/OVA-B. breve mice as
compared to the OVA/Sal-B. breve group (Figure 5B). A
significant increase in the expression of Foxp3 was observed
in the OVA/OVA-BUD group as compared to OVA/OVA-
PBS mice (Figure 5C). The expression of all Th-specific
transcription factors remained unchanged in the OVA/
Sal-L. rhamnosus and OVA/OVA-L. rhamnosus groups
(Figure 5D). Expression of Foxp3, however, was tightly
Figure 3 Beneficial bacteria modulate TLR and NLR mRNA expression in lung tissue of chronically asthmatic mice. Data is shown as
mean ± SEM, n = 6 mice/group, of the TLR and NLR mRNA expression levels in OVA-sensitised, Sal-challenged (OVA/Sal; white bars) mice and
OVA-sensitised, OVA-challenged (OVA/OVA; black bars) mice treated with PBS (A), B. breve (B), budesonide (C) or L. rhamnosus (D). The results are
presented as mRNA expression levels relative to levels found in the OVA/Sal-PBS mice (white bars in figure A). Statistical significance of
differences was tested using the post hoc Bonferroni’s multiple comparison test after one-way ANOVA. #Statistically significant difference (p < 0.05)
compared to the OVA/Sal-PBS group. ¤Statistically significant difference (p < 0.05) compared to the OVA/OVA-PBS group. ‡Statistically significant
difference (p < 0.05) compared to the OVA/Sal group in each treatment group.
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OVA/OVA-L. rhamnosus mice. None of the test groups
showed correlations between the expression of Gata3 and
Th2-related cytokines (Il4, Il5, Il13) and Rorγt and Th17-
related cytokines (Il17, Il23).
B. breve skews the immune response away from Th2 and
towards Treg in the lungs of chronically asthmatic mice
To determine the extent of Th response skewing in
the lung, ratios for Gata3/Tbet (Th2/Th1), Foxp3/
Rorγt (Treg/Th17), Foxp3/Gata3 (Treg/Th2) and
Foxp3/Tbet (Treg/Th1) mRNA expression were cal-
culated (Table 2). The OVA/OVA-PBS groups showed
a Th2-skewed immune response represented by a
significant increase in Gata3/Tbet ratio as compared
to OVA/Sal-PBS mice. This ratio was significantlydecreased in the OVA/OVA-L. rhamnosus and OVA/
OVA-B. breve groups, but not the OVA/OVA-budeso-
nide group. The Th2-reducing effect of OVA-OVA-B.
breve was even more effective in challenged mice
than healthy mice as the Gata3/Tbet ratio was de-
creased in OVA/OVA-B. breve mice as compared to
the OVA/Sal-B. breve group. This was not the case
for budesonide. Compared to the OVA/Sal-budesonide
group, there was a significant increase in the Gata3/
Tbet ratio in the OVA/OVA-budesonide group. Inter-
estingly, the Foxp3/Rorγt and Foxp3/Gata3 ratios
were significantly increased in OVA/OVA-B. breve
mice as compared to the OVA/OVA-PBS group indi-
cating an increase in Treg-associated responses. The
ratio of Foxp3/Tbet did not differ significantly among
the different treatment groups.
Figure 4 Beneficial bacteria and budesonide modulate cytokine mRNA expression in lung tissue of chronically asthmatic mice. Data is
shown as mean ± SEM, n = 6 mice/group, of the cytokine mRNA expression levels in OVA-sensitised, Sal-challenged (OVA/Sal; white bars) mice
and OVA-sensitised, OVA-challenged (OVA/OVA; black bars) mice treated with PBS (A), B. breve (B), budesonide (C) or L. rhamnosus (D). The
results are presented as mRNA expression levels relative to levels found in the OVA/Sal-PBS mice (white bars in figure A). Statistical significance
of differences was tested using the post hoc Bonferroni’s multiple comparison test after one-way ANOVA. #Statistically significant difference
(p < 0.05) compared to the OVA/Sal-PBS group. ¤Statistically significant difference (p < 0.05) compared to the OVA/OVA-PBS group. ‡Statistically
significant difference (p < 0.05) compared to the OVA/Sal group in each treatment group.
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http://respiratory-research.com/content/15/1/46Beneficial bacteria and budesonide increase Foxp3
expression in blood Treg cells of chronically asthmatic
mice
In order to determine if the transcriptional changes in-
duced in Foxp3 expression could be found at a protein ex-
pression level, flow cytometry was employed to examine
Foxp3 expression on Treg cells in the blood (Figure 6).
Treg cells were identified as CD4+ Foxp3 + CD25hi T cells
and the magnitude of Foxp3 expression on each cell was
determined by examining the mean fluorescence intensity
(MFI) of the Foxp3 staining. The percentage of CD4 cells
that are Foxp3+ did not differ among the different groups
(Figure 6A). The percentage of CD4 cells that are Foxp3+
and CD25hi was significantly decreased by all treatments
as compared to both OVA/Sal-PBS and OVA/OVA-PBS
groups (Figure 6B). However, all treatments increased theFoxp3 expression in the blood Treg cells. The staining in-
tensity of Foxp3 on day 56 was significantly higher in the
OVA/OVA-B. breve, OVA/OVA-BUD and OVA/OVA-
L. rhamnosus groups as compared to OVA/OVA-PBS
mice and to the OVA/Sal-PBS group (Figure 6C and D).
The staining intensity of Foxp3 on day 0 (before sensitisa-
tion, challenge and treatment) did not differ among the
different groups (data not shown).
B. breve and L. rhamnosus are as effective as budesonide
in suppressing mucosal mast cell degranulation in
chronically asthmatic mice
To examine the effect of the different treatments on
mast cells activity, enzyme-linked immunosorbent assay
was employed to measure mMCP-1 protein levels in
serum (Figure 7). The expression of mMCP-1 was
A B
C D
Figure 5 B. breve treatment up-regulates Tbet and Foxp3 mRNA expression in lungs of chronically asthmatic mice. Data is shown as
mean ± SEM, n = 6 mice/group, of the transcription factor mRNA expression levels in OVA-sensitised, Sal-challenged (OVA/Sal) mice and OVA-sensitised,
OVA-challenged (OVA/OVA) mice treated with PBS (A), B. breve (B), budesonide (C) or L. rhamnosus (D). The results are presented as mRNA expression
levels relative to levels found in the OVA/Sal-PBS mice (white bars in figure A). Statistical significance of differences was tested using the post hoc
Bonferroni’s multiple comparison test after one-way ANOVA. #Statistically significant difference (p < 0.05) compared to the OVA/Sal-PBS group.
¤Statistically significant difference (p < 0.05) compared to the OVA/OVA-PBS group. ‡Statistically significant difference (p < 0.05) compared to the OVA/Sal
group in each treatment group.
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pared to the OVA/Sal-PBS group. All treatments were
effective in suppressing mucosal mast cell degranulation
in OVA/OVA mice, as depicted by decreased protein
levels of mMCP-1 in serum when compared to the
OVA/OVA-PBS group. mMCP-1 levels in control ani-
mals (OVA/Sal) did not change after administration of
beneficial bacteria (data not shown).
Beneficial bacteria and budesonide reduce T cell activity
in chronically asthmatic mice
To investigate the effect of the treatments on cytokine
production by T cells in lung draining lymph nodes, TLN-
cell cultures were stimulated with anti-CD3, a pan T cell
stimulator, and the cytokine levels in the supernatant were
measured (Figure 8). Cytokine expression levels in
medium-stimulated TLN cells did not differ among the
different groups. The levels of IL-2, IL-4, IL-6, IL-17a,
TNF-α and IFN-γ were significantly increased in anti-
CD3-stimulated TLN cells of OVA/OVA-PBS mice as
compared to samples from the OVA/Sal-PBS group. All
treatments were effective in inhibiting T cell activity in
OVA/OVA mice, significantly decreasing the levels of
IL-2, IL-4, IL-6, IL-17a and TNF-α as compared to the
OVA/OVA-PBS group. Additionally, L. rhamnosus and
budesonide treatment significantly decreased the levels ofIFN-γ in OVA/OVA mice as compared to the OVA/OVA-
PBS group. IL-10 levels were increased (p > 0.05) in the
OVA/OVA-PBS and in all treatment groups as compared
to the OVA/Sal-PBS group. No differences in cytokine
expression were observed in the TLNs of the different
control groups (data not shown).
B. breve and L. rhamnosus are as effective as budesonide
in suppressing airway remodelling features in chronically
asthmatic mice
In order to examine the effect of the different treatments
on airway remodelling features, semi-quantivitive histo-
logical and immunhistochemical analyses of lung tissue
were performed (Figure 9 and Table 3). In the lung sec-
tions of OVA/OVA-PBS mice, increased inflammation
score and number of goblet cells, collagenous connective
tissue fibers, airway smooth muscle cells and prolifera-
ting cells was observed as compared to the OVA/Sal-
PBS group. All treatments were effective in reducing the
inflammation score and decreasing the number of col-
lagenous connective tissue fibers and proliferating cells
in sensitised and challenged mice as compared to
the OVA/OVA-PBS group. Yet, the number of airway
smooth muscle cells remained unchanged in the dif-
ferent treatment groups. Budesonide treatment was also
effective in reducing the number of goblet cells in the
Table 2 B. breve skews the immune response away from
Th2 and towards Treg in lungs of chronically asthmatic
mice
Treatment Ratio OVA/Sal OVA/OVA
Mean ratio SEM Mean ratio SEM
PBS Gata3/Tbet 1.03 0.10 1.66# 0.37
Foxp3/Rorγt 0.82 0.09 0.29 0.20
Foxp3/Gata3 0.83 0.09 0.41 0.28
Foxp3/Tbet 0.86 0.09 0.69 0.47
B. breve Gata3/Tbet 0.83 0.14 0.29¤, ‡ 0.02
Foxp3/Rorγt 1.62 0.36 2.36¤ 1.04
Foxp3/Gata3 1.65 0.36 2.92¤ 1.29
Foxp3/Tbet 1.36 0.30 0.83 0.37
budesonide Gata3/Tbet 0.78 0.10 1.34‡ 0.11
Foxp3/Rorγt 0.59 0.02 1.26 0.04
Foxp3/Gata3 0.66 0.02 1.00 0.03
Foxp3/Tbet 0.51 0.02 1.35 0.04
L. rhamnosus Gata3/Tbet 0.86 0.06 0.83¤ 0.08
Foxp3/Rorγt 1.02 0.22 1.07 0.21
Foxp3/Gata3 0.98 0.21 1.11 0.20
Foxp3/Tbet 0.84 0.18 0.92 0.18
Ratios for Gata3/Tbet (Th2/Th1), Foxp3/Rorγt (Treg/Th17), Foxp3/Gata3 (Treg/
Th2) and Foxp3/Tbet (Treg/Th1) mRNA expression in whole lung tissue are
shown for OVA/Sal and OVA/OVA mice for each treatment. Data is represented
as mean ratio ± SEM, n = 6 mice/group. The mean ratio was calculated by
dividing the individual expression values for the first transcription factor
(numerator) by the mean expression value for the second transcription factor
(denominator). Statistical significance of differences was tested using post hoc
Bonferroni’s multiple comparison test after one-way ANOVA. #Statistically
significant difference (p < 0.05) compared to the OVA/Sal-PBS group. ¤Statistically
significant difference (p < 0.05) compared to the OVA/OVA-PBS group. ‡Statistically
significant difference (p < 0.05) compared to OVA/Sal mice in each
treatment group.
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the OVA/OVA-PBS group.
Discussion
The aim of this study was to investigate the therapeutic ef-
fects of two different beneficial bacterial strains (B. breve
M-16 V and L. rhamnosus NutRes1) and a reference
treatment (budesonide) on features of the inflammatory
response and airway remodelling in a murine model for
chronic asthma. The lung resistance was significantly in-
creased in OVA/OVA-PBS mice at all concentrations of
methacholine as compared to the OVA/Sal-PBS group.
Additionally, the total inflammatory cell number and indi-
vidual BAL fluid cell counts, except lymphocytes, were
significantly increased in OVA/OVA-PBS mice. Increased
inflammation score and number of goblet cells, collage-
nous connective tissue fibers, airway smooth muscle cells
and proliferating cells was observed in lung sections of
these mice. Hence, our model mimics the airway in-
flammation and airway remodelling in chronic asthma[2,48,49]. Treatment with L. rhamnosus or B. breve, hardly
influenced the pathophysiological parameters in OVA/Sal-
PBS animals. Interestingly, L. rhamnosus and budesonide
treatments were effective in suppressing the lung resis-
tance in OVA/OVA mice, significantly decreasing the
AHR to methacholine as compared to the OVA/OVA-PBS
group. B. breve treatment did not affect the AHR to
methacholine. Airway inflammation is a characteristic fea-
ture of allergic asthma; however, the degree of airway in-
flammation is not always correlated with the degree of
AHR [50]. In the present study, we demonstrate that
L. rhamnosus prevents the ovalbumin-induced increase in
basal airway resistance and AHR at lower concentrations
of methacholine. In contrast to L. rhamnosus, B. breve was
not able to significantly reduce changes in airway resis-
tance. Although all the treatments were able to signifi-
cantly reduce airway inflammation by 50%, there was no
complete reduction up till control levels as shown in the
BAL fluid as well as in the histological evaluations. These
remaining cells might be responsible for the AHR at
higher concentrations of methacholine. There is no clear
explanation why L. rhamnosus did suppress the increase
in basal airway resistance and B. breve did not. Shifts in
cell type such as the reduction in the relative number of
macrophages or suppression of specific cytokines such as
IFN-γ might explain these observations. The above de-
scribed results are in accordance with other studies in
which beneficial bacteria and budesonide have been indi-
vidually investigated [1,13,23,24,51-53]. Additionally, B.
breve, L. rhamnosus and budesonide treatments reduced
the inflammation score and decreased the number of col-
lagenous connective tissue fibers and proliferating cells in
ovalbumin-sensitised and challenged mice as compared to
the OVA/OVA-PBS group. Budesonide treatment, but not
B. breve or L. rhamnosus, was also effective in reducing
the number of goblet cells in the lung sections of OVA/
OVA-budesonide mice. The number of airway smooth
muscle cells remained unchanged in the different treat-
ment groups as compared to OVA/OVA-mice.
To our knowledge, we demonstrate here for the first
time that L. rhamnosus NutRes1 is as effective as bude-
sonide in suppressing lung resistance in chronic allergic
mice. Additionally, we demonstrate here that both bene-
ficial bacterial strains are as effective as budesonide in
reducing chronic allergic inflammation by attenuating
the total inflammatory cell number as well as individual
BAL fluid cell counts; and airway remodelling.
PRRs are key components of the innate immunity
which are also involved in the activation and shaping of
adaptive immunity. The function and expression of PRRs
was linked to susceptibility towards allergic asthma. The
mRNA expression of Tlr3 and Nod1 was significantly de-
creased in the lungs of OVA/OVA-PBS mice. Previous
in vitro studies have demonstrated that upon activation
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Figure 6 Beneficial bacteria and budesonide increase Foxp3 expression in blood Treg cells of chronically asthmatic mice. T cells were
isolated on day 56 from mouse whole blood from OVA-sensitised, Sal-challenged (OVA/Sal) mice and OVA-sensitised, OVA-challenged (OVA/OVA)
mice for each treatment. (A) Percentage of CD4 cells that are Foxp3+. (B) Percentage of CD4 cells that are Foxp3+ and CD25hi. (C) Real mean
fluorescence intensity (MFI) of Foxp3 in Treg cells. (D) MFI levels relative to the OVA/Sal-PBS group (white bar). Data is shown as mean ± SEM,
n = 6 mice/group. Statistical significance of differences was tested using the post hoc Bonferroni’s multiple comparison test after one-way ANOVA.
#Statistically significant difference (p < 0.05) compared to the OVA/Sal-PBS group. ¤Statistically significant difference (p < 0.05) compared to the
OVA/OVA-PBS group. BUD = budesonide.
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Figure 7 Beneficial bacteria and budesonide reduce mouse
mast cell protease-1 levels in serum of chronic asthmatic mice.
Mouse serum was isolated on day 56 and mouse mast cell protease-1
(mMCP-1) levels were measured by ELISA. Data is shown as mean ±
SEM, n = 5-6mice/group. #Statistically significant difference (p < 0.05)
compared to the OVA/Sal-PBS group. ¤Statistically significant difference
(p < 0.05) compared to the OVA/OVA-PBS group. BUD = budesonide.
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http://respiratory-research.com/content/15/1/46by its natural or endogenous ligands, Tlr3 induces up-
regulation of other TLRs, various cytokines and che-
mokines as well as its own expression and thereby
contributes to exacerbation of inflammation [40]. Nod1
is an intracellular sensor of pathogenic bacteria. Single
nucleotide polymorphisms in Nod1 gene were positively
associated with susceptibility towards asthma in farming
children and this PRR was reported to be necessary for
neutrophil function in mice [25,33-35]. However, no direct
associations between Tlr3 and Nod1 expression and func-
tion and asthma have been reported yet, and whether the
decreased mRNA expression of Tlr3 and Nod1 caused by
the chronic inflammatory status of the animals is pro-
inflammatory or anti-inflammatory is also unknown.
Moreover, B. breve treatment significantly increased Tlr9
expression. Since TLR9 was shown to exert its immuno-
modulatory effects on asthma by skewing the increased
Th2/Th1 balance towards Th1, this may very well be the
situation [37-39]. Budesonide treatment significantly in-
creased the expression of Tlr3 and Nod1, restoring them
Figure 8 Beneficial bacteria and budesonide suppress cytokine production by T cells in TLNs of chronic asthmatic mice. Thoracic lymph
nodes (TLNs) were isolated from mice on day 56 and restimulated in vitro with plate-bound anti-CD3 monoclonal antibody or medium only for
5 days (37°C, 5% CO2). Data is shown as mean of cytokine concentration (ng/ml) ± SEM, n = 6 mice/group. Statistical significance of differences
was tested using post hoc Bonferroni’s multiple comparison test after one-way ANOVA. #Statistically significant difference (p < 0.05) compared to
the OVA/Sal-PBS group. ¤Statistically significant difference (p < 0.05) compared to the OVA/OVA-PBS group.
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http://respiratory-research.com/content/15/1/46to normal levels, and raised Tlr9 (P > 0.05) expression.
This further supports a positive role for Tlr9 and suggests
that lowered Tlr3 and Nod1 measured in the asthmatic
mice is pro-inflammatory in nature [25,34,40]. L. rhamno-
sus, besides significantly increasing Tlr3 expression and
increasing the expression of Tlr9 expression (P > 0.05),
significantly decreased the expression of Tlr4. Asthma pa-
tients have been shown to have low expression of TLR4
on their monocytes, lymphocytes and DCs suggesting that
this reduction in TLR4 activation might contribute to
the disease by reducing the release of Th1 and anti-
inflammatory cytokines [54]. These findings might suggest
that L. rhamnosus treatment in asthmatic mice could not
restore the expression of Tlr4 to its normal level. Taken
together, we demonstrate here that the mRNA expression
of PRRs in mouse lung tissue is differentially regulated by
the different treatments. Yet, all treatments, especially
B. breve, increased the expression of Tlr9.Th2 cells play a key role in the pathogenesis of allergic
asthma, and asthmatic patients were reported to have
Th1/Th2 imbalances as well as disturbed Th17/Treg
balances. Th2 dominance was observed in the OVA/
OVA-PBS group represented by a significant decrease in
Th1 and Treg transcription factors and high Gata3/Tbet
ratio. Hence, our model mimics the Th2-responses
found in chronic asthma [1,2]. Importantly, B. breve
shifted the immune balance towards Th1 and Treg, with
significantly increased Foxp3/Rorγt and Foxp3/Gata3
ratios and a significantly decreased Gata3/Tbet ratio. A
different strain of Bifidobacterium, B. animalis, has been
already shown to skew the Th1/Th2 balance towards
Th1 in a preventative, acute mouse model for respiratory
allergy [22]. Budesonide showed only a moderate effect
and significantly increased the expression of Foxp3, but
did not affect the Gata3/Tbet, Foxp3/Rorγt, Foxp3/
Gata3 and Foxp3/Tbet ratios. These findings are
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Figure 9 Beneficial bacteria and budesonide suppress airway remodelling features in chronic asthmatic mice. Representative
photomicrographs for 5 mice/group of hitstological and immunohistochemical staining for inflammation (hematoxylin-eosin, HE); goblet cells
(periodic acid Schiff, PAS); connective tissue (Masson trichrome, Masson); Anti-α-smooth muscle actin (α-smooth muscle) and proliferating cells
(Anti-Ki67) in lung tissue of sensitised only (OVA/Sal) and sensitised and challenged (OVA/OVA) mice treated with PBS, B. breve, L. rhamnosus or
budesonide (BUD). Original magnification, 40X, except for anti-Ki67 100X.
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shown that GCs treatment of asthmatic subjects encour-
ages regulatory responses [55]. L. rhamnosus did not in-
fluence the mRNA expression of the different Th-
specific transcription factors, but significantly decreased
the Gata3/Tbet ratio. More importantly, the above ob-
served effects of beneficial bacteria and budesonide on
the Th responses in the lung are mirrored by the detec-
tion of high Foxp3-expressing Tregs in the blood of
treated animals. Tregs play a key role in balancingTable 3 Overview of the hitstological and Immunohistochemi
Group Inflammation (HE) Goblet cells (PAS) Connecti
OVA/Sal-PBS - - -
OVA/OVA-PBS ++ + ++
OVA/Sal-B. breve - - +
OVA/OVA-B. breve + + +
OVA/Sal-L. rhamnosus - - +
OVA/OVA-L. rhamnosus + + +
OVA/Sal-budesonide - - +
OVA/OVA-budesonide + - +
Slides were reviewed in blinded fashion by two observers independently and slides
following way: −,no positive staining; +/−, less than 25% of cells stained positive; +
are presented as average score of 5 animals/group.immune responses and it was demonstrated that an in-
creased expression of Foxp3 in Tregs is directly associ-
ated with increased function of these cells [42,56]. No
significant differences in the percentage of CD4+ cells
that are Foxp3+ were observed. A reduction in the popu-
lations of recently activated regulatory T (CD4 + Foxp3 +
CD25hi) cells was observed in the treated mice. One pos-
sible reason for the loss of these cells may pertain to a re-
duction in inflammation caused by the treatments.
Previous studies have demonstrated that Tregs cancal score
ve tissue (Masson) α-smooth muscle cells
(anti-α-smooth muscle actin)
Proliferating cells
(anti-Ki67)
+ -
++ ++
+ +/−
++ +
+ +/−
++ +/−
+ +/−
++ +
were scored on the basis of the percentage of positive stained cells in the
,25 to 50% cells stained positive; ++, 50 to 75% cells stained positive. Results
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http://respiratory-research.com/content/15/1/46become activated through inflammatory signals in the
environment which functions as a natural feedback loop
by preventing excessive inflammation. An example of
this is through TLR2 stimulation [57].
Expression of the pro-inflammatory cytokines Il1β and
Il6 was significantly increased in the OVA/OVA-PBS
group and expression of both Il13 and Il17 was also in-
creased but not significantly. These four cytokines were
reported to enhance asthma [30]. B. breve treatment,
however, significantly increased the expression of the
anti-inflammatory cytokine Il10 and the Th2-associated
cytokine Il4, yet, the mRNA expression of Gata3 was de-
creased. Interestingly, the expression of Tbet was tightly
correlated with Ifnγ and Il12, while Foxp3 expression
was tightly correlated with Il10 expression. It has been
reported that IL-12 is involved in the differentiation of
Th1 cells and that these cells suppress Th2 cells through
the release of IFN-γ. Additionally, Tregs suppress other
Th cell effector functions through the release of IL-10
[30]. Budesonide treatment significantly decreased the
expression of the pro-inflammatory cytokine Tnfα which
is in agreement with previously published studies dem-
onstrating the anti-inflammatory effects of budesonide
[58]. L. rhamnosus treatment significantly decreased the
expression of Il6, another highly pro-inflammatory cyto-
kine. The mRNA expression of Foxp3 was tightly corre-
lated with Il10 expression.
Mast cells are key effector cells in allergic inflammation
and mast cell degranulation is detected in asthmatic lungs.
The expression of serum mMCP-1 was significantly in-
creased in OVA/OVA-PBS mice as compared to the
OVA/Sal-PBS group indicating pulmonary mast cell de-
granulation. Hence, previous studies demonstrated that
mice undergoing a hypersensitivity reaction in the airways
have high serum levels of mMCP-1 of pulmonary origin
[59]. All treatments were effective in inhibiting mucosal
mast cell degranulation, as shown by the significant de-
crease in the protein levels of mMCP-1 systemically, in
serum, in treated mice as compared to the OVA/OVA-
PBS group. The mechanism by which these beneficial
bacteria reduced mast cells degranulation still needs to
be investigated; yet, these effects might be galectines-
mediated. Recently, a combination of Bifidobacterium
breve M-16 V with galacto- and fructo-oligosaccharides
was shown to induce galectin-9 release from intestinal
epithelial cells which in turn systemically suppressed aller-
gic symptoms, including mast cells degranulation, in mice
and humans. The same study demonstrated a negative
correlation between increased serum galectin-9 levels and
serum mMCP-1 levels [60]. The mechanism by which
budesonide affects mast cell degranulation still needs fur-
ther investigation; yet, glucocorticoids were demonstrated
to suppress mast cell activation in vitro through the up-
regulation of inhibitory regulators of these cells [61]. Inaddition to their effects on mast cells, B. breve, L. rhamno-
sus and budesonide were also effective at reducing cyto-
kine production by T cells in the TLNs. The levels of IL-2,
IL-4, IL-6, IL-17a, TNF-α and IFN-γ were significantly in-
creased in anti-CD3-stimulated TLN cells from OVA/
OVA-PBS mice as compared to the OVA/Sal-PBS group.
IL-2, IL-4, IL-6, IL-17a and TNF-α were reported to be in-
volved in asthma. Increased levels of IFN-γ are found in
individuals with severe asthma and acute exacerbation
[30,62]. The levels of IL-2, IL-4, IL-6, IL-17a and TNF-α
were significantly decreased in OVA/OVA mice treated
with B. breve, L. rhamnosus or budesonide as compared to
the OVA/OVA-PBS group. Levels of IFN-γ were signifi-
cantly decreased in OVA/OVA-L. rhamnosus and OVA/
OVA-budesonide mice. The level of IL-10 did not differ
among the different groups, suggesting that the different
treatments could not normalise IL-10 production in
chronic allergic mice.
Conclusions
To our knowledge, this is the first report in which the
therapeutic effects of long-term treatment with B. breve
M-16 V, L. rhamnosus NutRes1 and budesonide on
asthma are investigated in a murine ovalbumin-induced
chronic allergic asthma model. In this current study we
show that B. breve M-16 V and L. rhamnosus NutRes1
are as effective as budesonide in suppressing pulmon-
ary airway inflammation, airway remodelling and
inhibiting mast cell degranulation. Additionally, L.
rhamnosus, but not B. breve, reduced lung resistance
and IFN-γ production by T cells in the TLNs indicating
that treatment effects differ between the bacterial
strains. mRNA expression of PRRs, T helper-specific
cytokines and transcription factors are differentially
modulated by the different treatments. Moreover, B.
breve induced regulatory responses by increasing Il10
and Foxp3 transcription in lung tissue and augmenting
the mean fluorescence intensity of Foxp3 in blood
CD4+ T cells. These findings show that B. breve
M-16 V and L. rhamnosus NutRes1 may be beneficial
in the management of chronic allergic asthma in a
therapeutic way.Additional files
Additional file 1: Table S1. Primers used for quantitative real-time PCR
analysis.
Additional file 2: Figure S1. Representative dot plots of T cells
analysis in the blood. T cells were isolated on day 56 from whole blood
of OVA-sensitised, Sal-challenged (OVA/Sal) mice and OVA-sensitised,
OVA-challenged (OVA/OVA) mice treated with PBS (I), B. breve (II),
L. rhamnosus (III) or budesonide (IV; BUD). T cells were gated based on
FSC-SSC pattern, followed by analysis of expression of CD4. Then
co-expression of Foxp3 and CD25 (regulatory T cells; Treg) was analyzed.
Data is representative for n = 6 mice/group.
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